Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease.

ABSTRACT: Amyloid β (Aβ) peptides have long been viewed as a potential target for Alzheimer's disease (AD). Aggregation of Aβ peptides in the brain tissue is believed to be an exclusively pathological process. Therefore, blocking the initial stages of Aβ peptide aggregation with small molecules could hold considerable promise as the starting point for the development of new therapies for AD. Recent rapid progresses in our understanding of toxic amyloid assembly provide a fresh impetus for this interesting approach. Here, we discuss the problems, challenges and new concepts in targeting Aβ peptides.

SUBMITTER: Nie Q

PROVIDER: S-EPMC4002509 | biostudies-other | 2011 May

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

Small-molecule sequestration of amyloid-β as a drug discovery strategy for Alzheimer's disease.

Project description:Disordered proteins are challenging therapeutic targets, and no drug is currently in clinical use that modifies the properties of their monomeric states. Here, we identify a small molecule (10074-G5) capable of binding and sequestering the intrinsically disordered amyloid-β (Aβ) peptide in its monomeric, soluble state. Our analysis reveals that this compound interacts with Aβ and inhibits both the primary and secondary nucleation pathways in its aggregation process. We characterize this interaction using biophysical experiments and integrative structural ensemble determination methods. We observe that this molecule increases the conformational entropy of monomeric Aβ while decreasing its hydrophobic surface area. We also show that it rescues a Caenorhabditis elegans model of Aβ-associated toxicity, consistent with the mechanism of action identified from the in silico and in vitro studies. These results illustrate the strategy of stabilizing the monomeric states of disordered proteins with small molecules to alter their behavior for therapeutic purposes.

| S-EPMC7673680 | biostudies-literature

Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy for Endometrial Cancer.

Project description:Endometrial cancer (EC) is the sixth most common cancer in women. A continued number of low-risk EC patients at diagnosis, as well as patients diagnosed with advanced-stage disease, will experience an aggressive disease. Unfortunately, those patients will present recurrence or overt dissemination. Systemic cytotoxic chemotherapy treatment on advanced, recurrent, or metastatic EC patients has shown poor results, with median survival rates of less than one year, and median progression-free survival rates of four months. Therefore, the search for innovative and alternative drugs or the development of combinatorial therapies involving new targeted drugs and standard regimens is imperative. Over the last few decades, some small-molecule inhibitors have been introduced in the clinics for cancer treatment, but only a few have been approved by the Food and Drug Administration (FDA) for EC treatment. In the present review, we present the current state and future prospects of small-molecule inhibitors on EC treatment, both alone and in combination.

| S-EPMC7598629 | biostudies-literature

Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies.

Project description:A potential strategy to alleviate the aggregation of intrinsically disordered proteins (IDPs) is to maintain the native functional state of the protein by small molecule binding. However, the targeting of the native state of IDPs by small molecules has been challenging due to their heterogeneous conformational ensembles. To tackle this challenge, we applied a high-throughput chemical microarray surface plasmon resonance imaging screen to detect the binding between small molecules and monomeric full-length Tau, a protein linked with the onset of a range of Tauopathies. The screen identified a novel set of drug-like fragment and lead-like compounds that bound to Tau. We verified that the majority of these hit compounds reduced the aggregation of different Tau constructs in vitro and in N2a cells. These results demonstrate that Tau is a viable receptor of drug-like small molecules. The drug discovery approach that we present can be applied to other IDPs linked to other misfolding diseases such as Alzheimer's and Parkinson's diseases.

| S-EPMC4976804 | biostudies-literature

Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies

| S-EPMC4997948 | biostudies-literature

Ameliorating amyloid aggregation through osmolytes as a probable therapeutic molecule against Alzheimer's disease and type 2 diabetes.

Project description:Large numbers of neurological and metabolic disorders occurring in humans are induced by the aberrant growth of aggregated or misfolded proteins. Alzheimer's disease (AD) and type 2 diabetes (T2D) are two of the most prevalent disorders that lead to toxic protofibrils of amyloid beta (Aβ) and human islet amyloid polypeptide (hIAPP) in the form of intrinsically disordered proteins (IDPs). IDPs are important functional proteins or peptides that have no common structures and are found in various organisms; they play an imperative role in multiple biological mechanisms, changing their folding and unfolding patterns depending on the environment. Osmolytes are low molecular weight naturally occurring small molecules present in almost all organisms that act as denaturants or counter-denaturants, helping to alter the environmental surroundings under stressful or pathological conditions. These molecules aid in imparting steadiness on accumulated proteins and defending them from aggregating. In the current study, we performed an advanced sampling technique, replica-exchange molecular dynamics (REMD) simulations, to investigate the activities of osmolytes, with guanidine hydrochloride (G-HCL) acting as a denaturant and l-proline (l-PRO) acting as a counter-denaturant, and to explore the regulation and aggregation of Aβ and hIAPP. We report that G-HCL and l-PRO have noticeable natural effects on Aβ and hIAPP, leading to conformation modulation. Our results highlight that G-HCL attenuates peptide aggregation and transitions peptides into unfolded conformations, while l-PRO helps produce folded conformations of Aβ and hIAPP.

| S-EPMC9050657 | biostudies-literature

Alzheimer's disease: the potential therapeutic role of the natural antibiotic amyloid-β peptide.

Project description: Not available

| S-EPMC5558531 | biostudies-literature

Small Molecule Catalysts with Therapeutic Potential.

Project description:Catalysts are employed in many areas of research and development where they combine high efficiency with often astonishing selectivity for their respective substrates. In biology, biocatalysts are omnipresent. Enzymes facilitate highly controlled, sophisticated cellular processes, such as metabolic conversions, sensing and signalling, and are prominent targets in drug development. In contrast, the therapeutic use of catalysts per se is still rather limited. Recent research has shown that small molecule catalytic agents able to modulate the redox state of the target cell bear considerable promise, particularly in the context of inflammatory and infectious diseases, stroke, ageing and even cancer. Rather than being "active" on their own in a more traditional sense, such agents develop their activity by initiating, promoting, enhancing or redirecting reactions between biomolecules already present in the cell, and their activity therefore depends critically on the predisposition of the target cell itself. Redox catalysts, for instance, preferably target cells with a distinct sensitivity towards changes in an already disturbed redox balance and/or increased levels of reactive oxygen species. Indeed, certain transition metal, chalcogen and quinone agents may activate an antioxidant response in normal cells whilst at the same time triggering apoptosis in cancer cells with a different pre-existing "biochemical redox signature" and closer to the internal redox threshold. In pharmacy, catalysts therefore stand out as promising lead structures, as sensor/effector agents which are highly effective, fairly selective, active in catalytic, i.e., often nanomolar concentrations and also very flexible in their structural design.

| S-EPMC6017662 | biostudies-other

Partial peptide of ?-synuclein modified with small-molecule inhibitors specifically inhibits amyloid fibrillation of ?-synuclein.

Project description:We have previously reported that pyrroloquinoline quinone (PQQ) prevents the amyloid formation of ?-synuclein, amyloid ?(1-42) (A?(1-42)), and mouse prion protein. Moreover, PQQ-modified ?-synuclein and a proteolytic fragment of the PQQ-modified ?-synuclein are able to inhibit the amyloid formation of ?-synuclein. Here, we identified the peptide sequences that play an important role as PQQ-modified specific peptide inhibitors of ?-synuclein. We demonstrate that the PQQ-modified ?-Syn(36-46) peptide, which is a partial sequence of ?-synuclein, prevented ?-synuclein amyloid fibril formation but did not inhibit A?(1-42) fibril formation. In addition, the ?-synuclein partial peptide modified with other small-molecule inhibitors, Baicalein and epigallocatechin gallate (EGCG), prevented ?-synuclein fibril formation. Currently reported quinone amyloid inhibitors do not have selectivity toward protein molecules. Therefore, our achievements provide a novel strategy for the development of targeted specific amyloid formation inhibitors: the combination of quinone compounds with specific peptide sequence from target proteins involved in amyloid formation.

| S-EPMC3588004 | biostudies-literature

Aggregation Mechanism of Alzheimer's Amyloid ?-Peptide Mediated by ?-Strand/?-Sheet Structure.

Project description:Alzheimer's disease (AD) is one of the most common neurodegenerative diseases and a widespread form of dementia. Aggregated forms of the amyloid ?-peptide (A?) are identified as a toxic species responsible for neuronal damage in AD. Extensive research has been conducted to reveal the aggregation mechanism of A?. However, the structure of pathological aggregates and the mechanism of aggregation are not well understood. Recently, experimental studies have confirmed that the ?-sheet structure in A? drives aggregation and toxicity in AD. However, how the ?-sheet structure is formed in A? and how it contributes to A? aggregation remains elusive. In the present study, molecular dynamics simulations suggest that A? adopts the ?-strand conformation by peptide-plane flipping. Multiple ?-strands interact through hydrogen bonding to form ?-sheets. This structure acts as a nucleus that initiates and promotes aggregation and fibrillation of A?. Our findings are supported by previous experimental as well as theoretical studies. This study provides valuable structural insights for the design of anti-AD drugs exploiting the ?-strand/?-sheet structure.

| S-EPMC7038184 | biostudies-literature

Development of small molecule inhibitors targeting PBX1 transcription signaling as a novel cancer therapeutic strategy.

Project description:PBX1 is a transcription factor involved in diverse cellular functions including organ development, stem cell renewal, and tumorigenesis. PBX1 is localized at chr1q23.3, a frequently amplified chromosomal region, and it is overexpressed in many human malignancies. Cancer cells with elevated PBX1 signaling are particularly vulnerable to PBX1 withdrawal. We designed a series of small molecule compounds capable of docking to the interface between PBX1 and its cognate DNA target sequence. Among them, T417 is found to be a lead compound. In cell-based assays, T417 significantly suppressed self-renewal and proliferation of cancer cells expressing high levels of PBX1. T417 also re-sensitized platinum-resistant ovarian tumors to carboplatin. T417 did not affect healthy tissues likely due to their lower PBX1 expression levels. Therefore, targeting PBX-DNA interface can be a promising strategy for treating human tumors reliant on PBX1 for survival.

| S-EPMC8591422 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data